Observational studyMedicine2025
Optical coherence tomography angiography findings in patients with acute nonarteritic central retinal artery occlusion treated with carbogen inhalation.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central retinal artery occlusion (CRAO), a retinal vascular disease that causes severe vision loss, can be evaluated by noninvasive modalities such as optical coherence tomography angiography (OCTA). However, no longitudinal quantitative studies have assessed OCTA in eyes with CRAO treated with carbogen inhalation. In this prospective, observational study, we evaluated the parametric changes of OCTA in patients with acute nonarteritic CRAO treated with carbogen inhalation. Best-corrected visual acuity and all OCTA parameters in eyes with acute nonarteritic CRAO were obtained before initiating carbogen inhalation, 12 to 24 hours and 36 to 48 hours after, and at 1 to 2 weeks and 4 to 6 weeks of follow-up. Twenty-five CRAO eyes were included. The initial OCTA showed reduced vessel density (VD) in both the superficial and deep capillary plexus in the whole-image area, parafovea, and perifovea, which remained decreased until 4 to 6 weeks. The VD at the fovea initially increased, followed by a reduction at 1 to 2 weeks and 4 to 6 weeks. Retinal edema was universal and improved at 1 to 2 weeks and 4 to 6 weeks. No VD recovery was observed after carbogen inhalation. Eyes with acute nonarteritic CRAO showed VD reduction, except at the fovea. No VD recovery was observed after carbogen inhalation. Baseline OCTA parameters did not predict favorable visual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.